Recursion Pharmaceuticals Inc (RXRX)

Currency in USD
4.60
+0.01(+0.22%)
Closed·
4.63+0.03(+0.65%)
·

RXRX Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.36 / -0.37
Revenue / Forecast
5.18M / 16.95M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2025--/-0.304--/24.51M----Free Sign Up
09/2025-0.36/-0.375.18M/16.95M+2.7%-69.44%Free Sign Up
06/2025-0.41/-0.3519.22M/15.37M-17.14%+25.05%Free Sign Up
03/2025-0.5/-0.4914.75M/14.98M-2.04%-1.54%Free Sign Up
12/2024-0.53/-0.414.55M/13.4M-29.27%-66.04%Free Sign Up
09/2024-0.34/-0.3326.1M/12.62M-3.03%+106.81%Free Sign Up
06/2024-0.4/-0.38414.4M/11.96M-4.09%+20.4%Free Sign Up
03/2024-0.39/-0.4213.79M/11.3M+7.14%+22.04%Free Sign Up
12/2023-0.42/-0.4610.89M/19.9M+8.7%-45.28%Free Sign Up
09/2023-0.43/-0.3910.53M/11.24M-10.26%-6.32%Free Sign Up

All numbers in USD

Recursion Pharmaceuticals Inc Earnings Call Summary for Q3/2025

  • Recursion Pharmaceuticals reported Q3 2025 with EPS of -$0.36 (beating -$0.37 forecast) but missed revenue targets significantly at $5.18M vs expected $16.95M, causing an 8.09% stock decline.
  • The company maintains a strong cash position of $785M with runway through 2027, committing to keep expenses below $450M in 2025 and $390M in 2026.
  • Incoming CEO Najat Khan emphasized translating the company's data and platform into 'tangible proof points,' while forecasting over $100M in partnership inflows by end-2026.
  • Despite effective cost management, Recursion faces significant revenue generation challenges and increasing competition in the AI-driven drug discovery sector.
  • The CDK7 program shows promise in oncology, with the company focusing on translating biological maps into therapeutic programs to advance its innovation pipeline.
Last Updated: 2025-11-05, 09:18 a/m
Read Full Transcript

FAQ

What Is Recursion Pharmaceuticals's Earnings Per Share (TTM)?

The Recursion Pharmaceuticals EPS (TTM) is -1.78.

When Is The Next Recursion Pharmaceuticals Earnings Date?

Recursion Pharmaceuticals will release its next earnings report on Mar 04, 2026.

What Is Recursion Pharmaceuticals’s Revenue Forecasts For Upcoming Quarters?

Recursion Pharmaceuticals’s revenue forecast is 16.28M.

How Did Recursion Pharmaceuticals React to the Company's Latest Earnings Report?

Recursion Pharmaceuticals reported a +2.7% EPS surprise and a -69.44% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -7.60%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.